Therefore, antigens such as β-catenin, MUC1, EGFR, FGFR, and PDGFR are sufficient targeted therapies for metastatic cancer cells, while E-cadherin is efficient for cancers in primary stages or after metastasis. This evidence concerns the gene MUC1 and cancer.